Group 1 - The National Vaccine and Biotechnology Index (980015) has seen a strong increase of 1.92%, with notable gains from stocks such as Zhaoyan New Drug (603127) up 8.41%, and Kanglong Chemical (300759) up 5.06% [1] - In the first half of 2025, 16 out of 28 A-share CXO companies reported a year-on-year increase in net profit, compared to only 7 companies in the same period last year [1] - The overall revenue of the medical R&D outsourcing sector grew by 13.77% year-on-year in the first half of 2025, with net profit attributable to shareholders increasing by 63.82% [1] Group 2 - The top ten weighted stocks in the National Vaccine and Biotechnology Index (980015) account for 64.01% of the index, including companies like Fosun Pharma (600196) and Changchun High-tech (000661) [2] - The Vaccine ETF Penghua (159657) closely tracks the National Vaccine and Biotechnology Index, which consists of 50 companies involved in the biotechnology industry [1]
疫苗ETF鹏华(159657)涨超2%，CRO概念震荡走高
Xin Lang Cai Jing·2025-09-05 04:22